The GIFT Nifty futures, which is an early indicator of the Nifty50 index, was trading 0.23% higher by 57 points at 24,603 indicating that the domestic benchmark indices are likely to make a positive start on Monday.

On Friday, 12 July, Domestic benchmark indices S&P BSE Sensex soared 622 points or 0.78%, to end at 80,519.35, while the Nifty50 traded 186 points or 0.77% higher and settled at 24,502.15.

Here are some stocks that are likely to remain in focus on 15 July.

HCL Technologies: In its quarterly earnings for April-June, the company reported a 2% year-on-year decline in its revenue from operations to Rs 28,057 crore, whereas the net profit during the quarter increased 7% YoY to Rs 4,257 crore. 

Rail Vikas Nigam: The company received a Letter of Acceptance (LoA) for overhead modification work up-gradation of the existing 1 x 25 kV electric traction system from Central Railway for a total consideration of Rs 132.59 crore. 

IREDA: In its quarterly earnings for the quarter ending 30 June, the company reported a 30% YoY growth to Rs 383.69 crore from Rs 294.58 crore reported in the same quarter of the previous fiscal year. 

Lupin: The company secured approval from the US Food and Drug Administration (USFDA) to market topiramate extended-release capsules, a generic medication used to treat seizures. 

Suven Pharma: Suven Pharmaceuticals received a Form 483 with two procedural observations following a US FDA inspection of Casper Pharma in Hyderabad and acquired a 51% stake in Sapala Organics.

Avenue Supermarts: The company that owns and operates D-Mart announced a 17.5% YoY increase in net profit to Rs 773.82 crore during Q1FY25 from Rs 658.71 crore reported in Q1FY24. 

Alembic Pharma: The company received tentative approval from the USFDA for its Selexipag for Injection, 1,800 mcg per vial, which is used to treat pulmonary arterial hypertension. 

Godrej Consumer Products: The company has launched its new mosquito repellent liquid vaporizers and agarbattis, using the indigenously developed and patented molecule Renofluthrin.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!